within Pharmacolibrary.Drugs.ATC.A;

model A03AD02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.24,
    Cl             = 81.6 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 80 / 1000000,
    adminCount     = 1,
    Vd             = 0.246,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.009166666666666667,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Drotaverine is a spasmolytic drug used to relieve smooth muscle spasm in various conditions, including gastrointestinal and genitourinary tract disorders such as irritable bowel syndrome and renal colic. It is structurally related to papaverine and used mainly in Central and Eastern Europe, South Asia, and Russia. It is not approved by the FDA for use in the USA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after a single oral dose.</p><h4>References</h4><ol><li><p>Bolaji, OO, et al., &amp; Ogunbona, FA (1996). Pharmacokinetics and bioavailability of drotaverine in humans. <i>European journal of drug metabolism and pharmacokinetics</i> 21(3) 217–221. DOI:<a href=&quot;https://doi.org/10.1007/BF03189716&quot;>10.1007/BF03189716</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8980918/&quot;>https://pubmed.ncbi.nlm.nih.gov/8980918</a></p></li><li><p>Vargay, Z, et al., &amp; Eckhardt, S (1984). The fate of drotaverine-acephyllinate in rat and man. II. Human pharmacokinetics of drotaverine-14C-acephyllinate. <i>European journal of drug metabolism and pharmacokinetics</i> 9(1) 17–29. DOI:<a href=&quot;https://doi.org/10.1007/BF03189602&quot;>10.1007/BF03189602</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6546919/&quot;>https://pubmed.ncbi.nlm.nih.gov/6546919</a></p></li><li><p>Dyderski, S, et al., &amp; Dubai, V (2004). Bioavailability study of drotaverine from capsule and tablet preparations in healthy volunteers. <i>Arzneimittel-Forschung</i> 54(5) 298–302. DOI:<a href=&quot;https://doi.org/10.1055/s-0031-1296974&quot;>10.1055/s-0031-1296974</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15212193/&quot;>https://pubmed.ncbi.nlm.nih.gov/15212193</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A03AD02;
